1. Home
  2. Companies
  3. SPL
  4. Material Events

Starpharma (ASX:SPL) — Material Events

ASX:SPL · 14 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 13 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
13
FDA Endorses Starpharma’s DEP® HER2 Phase 1 Trial Design Ahead of H2 2026 StartMedium
FDA endorses Starpharma's DEP® HER2 phase 1 clinical study design, enabling H2 2026 trial start
21 Apr 2026 ·Regulatory Update ·85
Starpharma Nets $5.5M Upfront in Genentech Oncology DealMedium
Starpharma secures $5.5M upfront from Genentech for oncology drug development collaboration
22 Oct 2025 ·License Agreement Announcement ·85
Starpharma Lands $8.5M Upfront Deal with Genentech, Eyes Clinical MilestonesHigh
Starpharma secures major Genentech and Radiopharm deals, advances clinical pipeline, reports solid cash position
28 Oct 2025 ·Quarterly Activities Report & Appendix 4C ·85
Starpharma and Radiopharm Forge $89M Radiotherapy CollaborationMedium
Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset with Potential $89M Milestones
30 Sept 2025 ·Research and Option Agreement Announcement ·85
Starpharma Turns Profit on Genentech Deal, Eyes 2026 Clinical MilestoneHigh
Starpharma reports H1 FY26 profit on Genentech deal, advances radiopharmaceutical pipeline
18 Feb 2026 ·Interim Report and Half Year Financial Results ·Unexpected ·85
Starpharma Hits DEP® Milestone Triggering $0.5 Million Option Fee from RadiopharmMedium
Starpharma milestone triggers AUD 0.5 million option fee from Radiopharm with potential AUD 91 million licensing deal
3 July 2026 ·Collaboration Milestone Announcement ·85
Starpharma Secures $5.5M Genentech Deal, Advances Radiotheranostics to ClinicMedium
Starpharma reports major partnerships, clinical progress, and revenue growth at 2025 AGM
14 Nov 2025 ·Annual General Meeting Presentation ·85
Starpharma and Genentech Forge $569M Oncology CollaborationMedium
Starpharma partners with Genentech in oncology drug development deal worth up to USD 569.5 million plus royalties
22 Sept 2025 ·Collaboration and License Agreement Announcement ·85
Starpharma and Genentech Forge $570M Cancer Therapy PartnershipMedium
Starpharma and Genentech Partner to Develop DEP®-Based Cancer Therapies with $5.5M Upfront and $564M Milestones
22 Sept 2025 ·Collaboration Agreement Announcement ·85
Starpharma Secures FDA Backing for DEP® HER2 Trial, Advances Partnerships and SalesMedium
Starpharma confirms FDA alignment for DEP® HER2 phase 1 trial, advances partnerships, reports $14.1M cash
29 Apr 2026 ·Quarterly Activities Report & Appendix 4C ·80
Starpharma Accelerates DEP® Asset Licensing Amid Global ExpansionMedium
Starpharma boosts FY25 revenue 165%, advances DEP® assets and expands global distribution
31 July 2025 ·Quarterly Activities Report & Appendix 4C ·80
Starpharma Accelerates Partnerships and Hits Record Viraleze™ Sales in Q2 FY26Medium
Starpharma advances partnerships, hits record Viraleze™ sales, and maintains strong cash position in Q2 FY26
29 Jan 2026 ·Quarterly Activities Report & Appendix 4C ·80
Starpharma’s FY25 Revenue Soars 183% as Loss Narrows to $10MMedium
Starpharma FY25 revenue surges 183%, loss narrows to $10M, cash at $15.4M
26 Aug 2025 ·Annual Report and Financial Results ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.